Early Detection: Dr. Harvey Pass
"We were able to use IPA's computational pathways analytics to develop network signatures from gene expression data and to identify a novel biomarker candidate for Mesothelioma," stated Dr. Harvey Pass, Professor of Cardiothoracic Surgery and Chief, Division of Thoracic Surgery and Thoracic Oncology at New York University. "Once we identify such biomarker candidates, we can look at larger cohorts of patients for further validation. We believe this Ingenuity methodology, which was used to find Osteopontin as a Mesothelioma marker as described in the New England Journal of Medicine, will become a standard protocol for biomarker discovery."
Additional Information
NYU Study Validates Use Of Fujirebio Diagnostics' MESOMARK Test For Monitoring An Asbestos-Linked Cancer (3/12/07)
Results from a recent study conducted by researchers at New York University (NYU) School of Medicine show the MESOMARK Assay, the world's first and only in vitro test for monitoring mesothelioma developed by Fujirebio Diagnostics, Inc., is an effective way to measure proteins within the blood that reflect changes in disease. The findings represent a major milestone in the management of mesothelioma, as the test may enable doctors to more accurately monitor patients for treatment. More...
Osteopontin: Marker for Mesothelioma (7/18/06)
According to a recent article published in the New England Journal of Medicine, the protein osteopontin, which can be found in circulating blood, may help in the early detection of mesothelioma. However, further studies are necessary to confirm osteopontin as a reliable marker as well as to determine if outcomes for patients can be improved through the use of this marker. More...
Ingenuity Systems Launches Biomarker Workflow Guide (5/10/06)
Ingenuity Systems launches its biomarker workflow guide to formalize its ongoing biomarker initiative. Scientists will be able to utilize Ingenuity Pathways Analysis to identify potentially useful biomarkers during the preclinical exploratory phase via analysis of gene expression array data or proteomics data. More...